VEON Settles $19.97M Class Action Over ADR Purchases

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

VEON settles $19.97M class action lawsuit over ADR purchases from 2011-2015. Eligible investors must submit claims by April 28, 2026.

VEON Settles $19.97M Class Action Over ADR Purchases

The United States District Court for the Southern District of New York has approved a proposed class action settlement valued at $19.97 million for investors who purchased American Depositary Shares of VEON Ltd. during the period spanning June 30, 2011, through November 3, 2015. The settlement resolves claims related to the company's securities during this timeframe.

Investors eligible to participate in the settlement must submit claim forms by April 28, 2026, to receive distributions from the settlement fund. A final approval hearing is scheduled for May 19, 2026, where the court will determine whether to grant final authorization of the settlement agreement. Class members are advised to monitor filing deadlines to ensure their eligibility for compensation.

The settlement provides a resolution to the litigation without admission of wrongdoing by the defendants. Investors who believe they qualify as class members are encouraged to review settlement documentation and submit required claim forms within the specified timeframe.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 19

Related Coverage

GlobeNewswire Inc.

Shareholder Lawsuits Mount Against Kyndryl, uniQure as Lead Plaintiff Deadlines Loom

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

KDBRBRMETC
GlobeNewswire Inc.

Legal Battle Heats Up: Major Shareholder Suits Filed Against $BRBR, $BYND, and $METC

Three shareholder lawsuits filed against $BRBR, $BYND, and $METC over alleged sales misstatements, asset valuations, and mine development disclosures. Lead plaintiff deadlines announced; affected investors encouraged to seek legal representation.

BRBRMETCMETCB
GlobeNewswire Inc.

Expensify Faces $9.5M IPO Settlement Over Registration Statement Violations

Federal court approves $9.5M class action settlement for Expensify IPO purchasers over alleged registration statement inaccuracies, with fairness hearing scheduled June 2026.

EXFY
GlobeNewswire Inc.

$BIOXCEL Settlement: $9.75M Class Action Approved for Securities Fraud Claims

BioXcel Therapeutics settles $9.75M class action over securities purchased March-June 2023. Fairness hearing scheduled September 2026.

BTAI
GlobeNewswire Inc.

Biogen Class Action Certified: Securities Lawsuit Over 2021 Misrepresentation Claims

Federal court certifies class action against Biogen for alleged 2021 securities misrepresentations, affecting purchasers during June-July period.

BIIB
GlobeNewswire Inc.

Shareholder Lawsuits Against NKTR, EOSE Highlight Trial Disclosure and Guidance Risks

Shareholder lawsuits against Nektar Therapeutics ($NKTR) and Eos Energy ($EOSE) allege clinical trial and production capacity disclosure failures, with lead plaintiff deadlines in April-May 2026.

EOSENKTR